| Disease | DRUG'S THERAPEUTIC PROFILE WAS THUS FOUND TO BE SIMILAR TO THE PRFILE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS.
PARTICULARLY EFFECTIVE IN THE CORE SYMPTOMS OF THE DISORDER. THE RESULTS INDICATE THAT HYPERICUM EXTRACT ACCELERATED THE RECOVERY FROM DEPRESSION IN A RATHER GENERAL MANNER, BY INFLUENCING ALL INVESTIGATED SIGNS AND SYMPTOMS OF THE DISEASE. THE
4,5,6,9,10,11,15,17) WAS PRIMARILY COMPOSED OF ITEMS ASSESSING DEPRESSION-RELATED ANXIETY AND INSOMNIA. IN BOTH CLUSTERS, HYPERICUM EXTRACT REDUCED THE SYMPTOMS OF DEPRESSION MORE EFFECTIVELY THAN PLACEBO. HOWEVER, THE HERBAL DRUG WAS
WERE IDENTIFIED WHICH WERE STABLE IN SEVERAL INDEPDENT SUBSETS OF THE FULL DATA SET. WHILE CLUSTER 1 (HAMD ITEMS 1,2,3, 7,8,12,13,14,16) WAS INTERPRETED TO REPRESENT THE CORE SYMPTOMS OF DEPRESSION (INDLUDING SOMATIC ASPECTS), CLUSTER 2 (ITEMS
(HAMD, 17-ITEM VERSION) BETWEEN BASELINE AND TREATMENT END. THE RELATIONSHIP BETWEEN THE SYMPTOMS OF DEPRESSION REPRESENTED BY THE ITEMS OF THE HAMD WAS ASSESSED BY MEANS OF CLUSTER ANALYSIS AND INDIVIDUAL ITEM ANALYSIS. TWO CLUSTERS OF ITEMS
EXTRACT (WS 5570 OR WS 5572) OR PLACEBO OVER A DOUBLE-BLIND TREATMENT PERIOD FOR 6 WEEKS. THE PRIMARY OUTCOME MEASURE FOR TREATMENT EFFECACY IN THE ORIGINAL TRIALS WAS THE CHANGE IN THE TOTAL SCORE OF THE HAMILTON RATING SCALE FOR DEPRESSION
A META-ANALYSIS WAS PERFORMED ON THE ORIGINAL DATA OF THREE DOUBLE-BLIND, RANDOMIZED MULTICENTER TRAILS, DURING WHICH 544 OUT-PATIENTS SUFFERING FROM MILD TO MODERATE DEPRESSION ACCORDING TO DSM-IV CRITERIA RECEIVED 32300 MG/DAY HYPREICUM |